BWG
PACB icon

Beta Wealth Group’s Pacific Biosciences PACB Stock Holding History

Beta Wealth Group’s Portfolio PACB Stock Details PACB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-19,000
Closed -$24.3K – 122
2025
Q3 		$24.3K Buy
+19,000
New +$25.7K 0.01% 116

Other funds holding PACB

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Beta Wealth Group's PACB Position: Q4 2025 in Review

Beta Wealth Group sold out of Pacific Biosciences (PACB) in Q4 2025, closing a stake of 19,000 shares — an estimated $24.3K sold.

Beta Wealth Group first reported a position in PACB in Q3 2025 and held it in 1 quarter. The position peaked at $24.3K in Q3 2025. 215 funds tracked by Wall St. Rank hold PACB as of Q4 2025.

  • Beta Wealth Group reported no remaining Pacific Biosciences position as of Q4 2025 after selling out during the quarter.
  • Beta Wealth Group sold 19,000 Pacific Biosciences shares in Q4 2025, an estimated $24.3K.
  • Beta Wealth Group first reported a position in Pacific Biosciences in Q3 2025 and held it in 1 quarter.
  • Beta Wealth Group's Pacific Biosciences position peaked at $24.3K in Q3 2025.
  • 215 funds tracked by Wall St. Rank held Pacific Biosciences as of Q4 2025.

Based on Beta Wealth Group's 13F filing for Q4 2025, filed 13 Feb 2026.